AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TCJ2

UPID:

STT3B_HUMAN

Alternative names:

Source of immunodominant MHC-associated peptides homolog

Alternative UPACC:

Q8TCJ2; Q96JZ4; Q96KY7

Background:

Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit STT3B plays a pivotal role in protein N-glycosylation, a process critical for protein folding and stability. It acts as the catalytic subunit within the oligosaccharyl transferase complex, facilitating the transfer of glycan chains to nascent proteins, essential for their proper function and localization. Its activity is crucial in both co- and post-translational modifications, impacting a wide array of biological processes.

Therapeutic significance:

Given its central role in glycoprotein biosynthesis, STT3B's dysfunction is linked to Congenital disorder of glycosylation 1X, manifesting in severe developmental and systemic anomalies. Understanding the role of STT3B could open doors to potential therapeutic strategies, offering hope for targeted interventions in glycosylation disorders and enhancing our approach to precision medicine.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.